PatientsMap 2018 CHINA Data analysis part 2

PRESS RELEASE

February 27th 2019

Social Survey Research Information Co., Ltd.

 
 

PatientsMap 2018 CHINA Data analysis part 2

Manufacturer cover ranking per department

Visitation rate of Sales Rep of Japanese companies to Chinese doctors

Santen stands out as a top company with 63% in ophthalmology

In other Japanese companies, Astellas ranked 4th with 33% in urology, Eisai ranked 5th with 29% in neurology

 

Looking at the top 5 rankings for the 10 departments from all 32 target departments, while global major companies such as AZ, Pfizer and Bayer are in the top position, some Chinese companies such as CTTQ also ranked high.

As for Japanese companies, Santen was first place with 62.8% in ophthalmology. And Astellas came in fourth in urology and Eisai in fifth in neurology. (fig 1)

After the 6th place, Otsuka was 7th place in psychiatry, Dainippon Sumitomo was 9th place, Daiichi Sankyo was 9th place in respiratory, Takeda was 11th place in urology, etc. The result shows that Japanese companies seem to be penetrating the Chinese market

In the future, we plan to provide analysis data on MR coverage for all 32 medical departments in China for companies in Europe, the United States and Europe.

Table 1. Top 5 companies ranking in 10 top medical departments for Sales Rep visit recognition based on Patients Map2018 CN

 
Rank Internal Medicine  Dept.
n=1328
Respiratory Dept.
n=414
Gastroenterology Dept.
n=476
Cardiology Dept.
n=1105
Diabetology/
Endocrinology Dept.
n= 536
1 Bayer 29.7 AZ 55.8 AZ 48.7 AZ 55.5 Novo 64.6
2 Pfizer 26.8 Pfizer 47.3 CTTQ 30.0 Pfizer 54.0 Bayer 54.3
3 AZ 26.7 GSK 45.2 Bayer 25.8 Bayer 51.1 Sanofi 52.4
4 Novo 20.4 Bayer 41.3 GSK 25.4 Sanofi 41.6 Eli Lilly 48.7
5 Sanofi 20.0 MSD 35.3 Janssen 21.0 Novartis 34.4 AZ 38.2
Psychiatry Dept.
n=436
Neurology Dept.
n=1046
Hematology Dept.
n=214
Ophthalmology Dept.
n=172
Urology Dept.
n=200
1 Janssen 59.0 Pfizer 51.0 Pfizer 58.4 Santen 62.8 MSD 44.0
2 Eli Lilly 41.5 Bayer 46.0 Janssen 57.5 Novartis 55.8 AZ 43.5
3 JHP 41.2 Sanofi 35.5 CTTQ 53.3 Pfizer 19.8 Pfizer 39.0
4 Pfizer 37.6 AZ 34.3 MSD 51.4 Qilu 16.9 Astellas 33.0
5 Qilu 25.5 Eisai 28.7 Novartis 47.7 Eisai 14.5 Janssen 28.5
 
 
<Reference: July 5, 2018 Press Release>
Table 2. PatientsMap2018 CN- Top 15 Sales Rep visit ranking(n=10,285)
Overall rank Company name N=
1 Pfizer 3,626 35.3%
2 Astra Zeneca 3,229 31.4%
3 Bayer 3,123 30.4%
4 MSD 2,381 23.2%
5 Sanofi 2,134 20.7%
6 Novartis 1,954 19.0%
7 GlaxoSmithKline 1,736 16.9%
8 CHIA TAI TIANQING (CTTQ) Pharmaceutical 1,675 16.3%
9 Roche 1,651 16.1%
10 Yangtze River Pharmaceutical (Group) 1,618 15.7%
11 Janssen 1,598 15.5%
12 Qilu Pharmaceutical 1,413 13.7%
13 Eli Lilyイ 1,398 13.6%
14 Novo Nordisk 1,244 12.1%
15 Jiangsu Hengrui Medicine Distribution 1,176 11.4%
 
Table 3. PatientsMap2018 CN- Top 15 Sales Rep visit ranking- Japanese companies(n=10,285)
Overall rank Company name n=
21 Eisai 836 8.1%
27 Takeda 488 4.7%
30 Daiichi Sankyo 480 4.7%
32 Otsuka 401 3.9%
37 Sumitomo Dainippon Pharma 340 3.3%
43 Astellas 232 2.3%
47 Santen 162 1.6%

_______________________________________

 

“PatientsMap 2018CN” – Outline-

The respondents of this study was randomly selected per specialty/department from members of medlive.cn, administrated by Chinese affliate of m3.com and is a portal site for healthcare professionals with 2,130,000 online members,.

 

Studied medical conditions:           357 conditions

 

Sample source:                              M3 Global Research online physician panel

 

Sample department:                      All departments in hospitals and clinics

 

Methodology:                                  Online survey

 

Sample size:                                   Total of 10,285 physicians

 

Fieldwork schedule:                        3rd January 2018~6th March 2018

 

Contents of the survey:                  Medical conditions that they treat

 

Number of patients they see per medical condition

 

Number of patients in which they administer medicine to

 

Medical conditions in which they wish for new products

 

Sales rep visitation status
  • This service is provided jointly by Social Survey Research Co., Ltd., M3, Inc. and M3 Global Research.

 

Contact Information   Social Survey Research Information Co., Ltd

 

Contact: Chiharu Sakai

 

℡:03-6709-9710

 

e-mail:patientsmap@ssri.com

 

 

 
  • Social Survey Research Information Co., Ltd

 

Established         April 1982

 

Capital                 27 million yen

 

Executive            President & CEO Takashi Makita

 

Staff                     110 staff members

 

Address               NMF Shinjuku EAST Bldg.

 

10-5 Tomihisacho, Shinjuku-ku, Tokyo 162-0067

 

JAPAN

 

Osaka Office        Tetsutani Bldg. 502

 

2-2-2 Tokui-cho, Chuo-ku, Osaka540-0025

 

JAPAN

 

 

 

Affiliate companies PD Research Co., Ltd.

 

SSRI-CHINA Co., Ltd.

URL                  http://www.ssri.com/index.html

 

 
  • M3, Inc.

 

Established          September 2000

 

Capital                 15 billion and 31 million yen

 

Director               Representative Director Itaru Tanimura

 

Subsidiaries staff               3,556 staff members (as of end of March 2016)

 

Address               Akasaka Intercity 10th floor

 

1-11-44 Akasaka

 

Minato-ku, Tokyo 107-0052

 

JAPAN

 

URL                      http://corporate.m3.com/

 

 
  • Medlive.cn

Established: April 2013

 

Capital: 2 million CNY

 

General manager: Tian Liping

 

Number of staffs: 210

 

Address: Beijing Red Manor International Bonded Innovation Park E-1,

 

Baijialou 1, Chaoyang North Road, Chaoyang District,

 

Beijing 100024

 

URL: http://www.medlive.cn/

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *